SuperworthQ32 Bio price to sales ratio QTTB
Market value divided by revenue over the last twelve months, since 2019.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 80.7×
- Apr 2024
- 7-year median
- 19.1×
- 7-year range
- 2.4× to 200×
- Peer median
- 1.4×
Q32 Bio's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Apr 2024, at 80.7×.
On the days it had one over the last 7 years, its median was 19.1×, from 2.4× in May 2022 to 200× in Mar 2021.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 80.7× | 17.3× | 80.7× |
| 2023 | 18.0× | 15.2× | 30.3× |
| 2022 | 22.6× | 2.4× | 39.9× |
| 2021 | 6.1× | 6.1× | 200× |
| 2020 | 194× | 194× | 199× |
| 2019 | 194× | 194× | 194× |
Against its peers
Companies in Drug Manufacturers - General nearest Q32 Bio's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| QTTBQ32 Bio | n/m |
| NATRNatures Sunshine Products | 0.4× |
| ARVNArvinas | 1.5× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| CRMDCorMedix | 1.3× |
| COLLCollegium Pharmaceutical | 0.9× |
| ABUSArbutus Biopharma | 4.6× |
| LFVNLifevantage | 0.4× |
| SPROSpero Therapeutics | 1.4× |
| Peer median | 1.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Q32 Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.